These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35984626)

  • 1. High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers.
    Kokolakis G; Kreis G; Falqués M; Aparici M; Sondermann W
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2135-2144. PubMed ID: 35984626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
    Portron A; Jordan P; Draper K; Muenzer C; Dickerson D; van Iersel T; Hofmann C
    Clin Ther; 2020 Jan; 42(1):108-120.e1. PubMed ID: 31883703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects.
    Khalilieh S; Hodsman P; Xu C; Tzontcheva A; Glasgow S; Montgomery D
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):294-300. PubMed ID: 29510001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
    Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
    Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects.
    Zandvliet A; Glasgow S; Horowitz A; Montgomery D; Marjason J; Mehta A; Xu C; van Vugt M; Khalilieh S
    Int J Clin Pharmacol Ther; 2015 Feb; 53(2):139-46. PubMed ID: 25546162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial.
    Kivitz A; Cohen S; Dowd JE; Edwards W; Thakker S; Wellborne FR; Renz CL; Segurado OG
    Clin Ther; 2006 Oct; 28(10):1619-29. PubMed ID: 17157117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects.
    Dias C; Abosaleem B; Crispino C; Gao B; Shaywitz A
    AAPS PharmSciTech; 2015 Oct; 16(5):1101-7. PubMed ID: 25693652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers.
    Berteau C; Schwarzenbach F; Donazzolo Y; Latreille M; Berube J; Abry H; Cotten J; Feger C; Laurent PE
    Patient Prefer Adherence; 2010 Oct; 4():379-88. PubMed ID: 21049090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
    Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
    Dychter SS; Harrigan R; Bahn JD; Printz MA; Sugarman BJ; DeNoia E; Haughey DB; Fellows D; Maneval DC
    Clin Ther; 2014 Feb; 36(2):211-24. PubMed ID: 24486335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-acting pegylated recombinant human growth hormone (Jintrolong
    Guan Y; He F; Wu J; Zhao L; Wang X; Huang L; Zeng G; Ren B; Chen J; Liao X; Ma Z; Chen X; Zhong G; Huang M; Zhao X
    J Clin Pharm Ther; 2018 Oct; 43(5):640-646. PubMed ID: 29959799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
    Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
    Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
    Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
    Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.
    Gillet Y; Habermehl P; Thomas S; Eymin C; Fiquet A
    BMC Med; 2009 Apr; 7():16. PubMed ID: 19366435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects.
    Sabet A; Dickerson DS; Kunina EE; Buccarello AL; Monnet J
    Rheumatol Ther; 2022 Apr; 9(2):693-704. PubMed ID: 35262901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
    Berges A; Walls C; Lener SE; McDonald SA
    Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients.
    Bruin G; Hockey HP; La Stella P; Sigurgeirsson B; Fu R; Patekar M; Charef P; Woessner R; Boutouyrie-Dumont B
    Br J Clin Pharmacol; 2020 Feb; 86(2):338-351. PubMed ID: 31658377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study.
    Vermeire S; D'heygere F; Nakad A; Franchimont D; Fontaine F; Louis E; Van Hootegem P; Dewit O; Lambrecht G; Strubbe B; Baert F
    Patient Prefer Adherence; 2018; 12():1193-1202. PubMed ID: 30013330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
    Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
    BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.